MINOXIDIL (FOR WOMEN)
Clinical safety rating: safe
Other antihypertensive drugs can have additive effects Can cause pericardial effusion and hypertrichosis.
Minoxidil is a potassium channel opener. It activates ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arterioles, causing peripheral vasodilation and reduced blood pressure. For hair growth, the exact mechanism is unclear but involves increased cutaneous blood flow, stimulation of hair follicle proliferation via direct effects on dermal papilla cells, and prolongation of the anagen phase.
| Metabolism | Minoxidil is primarily metabolized by conjugation with glucuronic acid to minoxidil glucuronide, which is thought to be mediated by UDP-glucuronosyltransferases (UGTs). A minor pathway involves sulfation. The parent drug and metabolites are excreted renally. |
| Excretion | Primarily renal (90% as unchanged drug and metabolites; 10% via feces via biliary elimination). |
| Half-life | Terminal elimination half-life: approximately 4.2 hours in patients with normal renal function; may extend to 24+ hours in renal impairment. |
| Protein binding | Negligible (~0% binding to plasma proteins). |
| Volume of Distribution | 3 L/kg (suggests extensive extravascular distribution; high tissue binding). |
| Bioavailability | Topical: <1.5% systemic absorption at recommended dose (1 mL of 2% solution). Oral: ~90% (not indicated for women). |
| Onset of Action | Topical: 4 months (hair regrowth observable); oral (not indicated for women but data): 1–2 hours for vasodilation. |
| Duration of Action | Topical: Continuous use required; effects reverse 3–4 months after discontinuation. Oral: 4–6 hours per dose. |
Topical: 2% or 5% solution, 1 mL applied to the scalp twice daily (morning and evening).
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No specific recommendations. Use with caution in end-stage renal disease due to potential for systemic absorption. |
| Liver impairment | No specific dose adjustment recommendations. Caution in severe hepatic impairment. |
| Pediatric use | Not indicated for use in children <18 years of age. |
| Geriatric use | No specific adjustments; hypoalbuminemia in elderly may increase sensitivity to adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other antihypertensive drugs can have additive effects Can cause pericardial effusion and hypertrichosis.
| FDA category | Animal |
| Breastfeeding | Minoxidil is excreted into breast milk in small amounts. The milk-to-plasma ratio is estimated at 0.15–0.2. In one study, peak milk concentration was 21 ng/mL after a 5 mg oral dose (topical doses are lower). Theoretical risk to infant includes hypotensive effects and hypertrichosis. Topical use likely results in negligible systemic absorption, but caution is advised. American Academy of Pediatrics considers topical use compatible with breastfeeding. |
■ FDA Black Box Warning
None
| Common Effects | androgenetic alopecia |
| Serious Effects |
["Hypersensitivity to minoxidil or any component of the formulation","Application to broken, irritated, or sunburned scalp","Concomitant use of other topical agents on the same area","Relative: Severe cardiovascular disease, hypotension, or concurrent use of antihypertensives (systemic effects possible)"]
| Precautions | ["Cardiac effects: Minoxidil can cause tachycardia, fluid retention, and pericardial effusion when used systemically; topical use has minimal systemic absorption but caution in patients with cardiovascular disease","Hypertrichosis: Unwanted facial and body hair growth can occur with topical use, especially if applied to broken skin or in higher doses","Scalp irritation: Contact dermatitis, itching, redness, or burning at application site","Accidental ingestion: Children and pets are at risk of severe adverse effects if ingested","Pregnancy: Limited data; use only if clearly needed","Lactation: Unknown if excreted in breast milk; caution advised"] |
Loading safety data…
| Teratogenic Risk |
| Teratogenic potential in pregnant women is not definitively established. Animal studies have shown fetal abnormalities (e.g., skeletal malformations) at high doses. In humans, there is limited data; however, case reports suggest possible fetal adverse effects including hypertrichosis and neonatal hypotension when used near term. Minoxidil is categorized as FDA Pregnancy Category C. First trimester: unknown risk; second and third trimesters: potential for fetal effects, especially if used chronically. |
| Fetal Monitoring | For pregnant women using minoxidil, monitor blood pressure regularly due to potential hypotensive effect. Assess fetal growth and amniotic fluid volume via ultrasound if long-term use occurs. In neonates exposed near term, monitor for hypotension and hypertrichosis. Assess maternal fluid status and electrolytes if high doses are used for hypertension. |
| Fertility Effects | No significant adverse effects on fertility have been reported in humans. Animal studies at high doses showed no impairment of fertility. Minoxidil is not known to affect ovulation or spermatogenesis. However, hypertrichosis may cause cosmetic concerns but does not impair reproductive function. |